Brief: Scynexis Q3 EPS USD -0.04
13/11/2023 22:18
Nov 13 (Reuters) - Scynexis Q3 net income USD -1.757 million. * Q3 pretax profit USD -1.757 million * Q3 basic EPS USD -0.04 * Q3 operating expenses USD 11.859 million
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview